AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06415851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody
Description: This study is a single-arm intervention study. All subjects in this study will be treated with this study protocol, that is, after mFOLFOX6 protocol and bevacizumab induction therapy, combined with slulimumab treatment.
Study NCT05599919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitric Oxide
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
Study NCT05599919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: The Sponsor designed a dual chamber nasal spray bottle for NORS administration. Components are mixed from two chambers to create the final NO-producing formulation. The liquid contains NO at 0.11 ppm\*hour, which acts as a viricidal agent. Instructions for storing, preparing, and administering the study treatment will be provided to participants.
Study NCT05287542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnotic suggestion
Description: The intervention group will receive four weekly 60 min. sessions with hypnosis treatment including induction followed by hypnotic suggestion.
Study NCT05287542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: The active control group will receive four weekly 60 min. sessions of induction and mindfulness-based instructions.
Study NCT05130944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Entre Nosotras
Description: A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women.
Study NCT05130944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Entre Nosotras
Description: A series of five 2-hour group sessions that are administered weekly by two trained female peer facilitators, who are selected by HIAS outreach workers and/or community leaders. The content of the sessions is based on the principles of Psychological First Aid and the Participatory Action Cycle, which is intended to generate community-led problem solving around priority issues affecting their wellbeing.~Entre Nosotras is a community- and strengths-based intervention designed to mobilize social support, strengthen community connectedness, and stimulate collective action to promote the safety and wellbeing of women.
Study NCT05130944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doing What Matters in Times of Stress
Description: The stress management components are derived from the World Health Organization Doing What Matters in Times of Stress illustrated guide for coping with adversity (World Health Organization, 2020). The illustrated guide and accompanying audio files are publicly available: https://www.who.int/publications/i/item/9789240003927. During five sessions, the intervention involves 15-20 minute exercises covering a range of stress management and coping skills.
Study NCT06461429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Antibiotic. Standard of care. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Study NCT06461429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin and Erythromycin
Description: Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Study NCT06461429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Antibiotic. Antibiotics will be administered for 7 days or until delivery (whichever is sooner).
Study NCT05509712 — intervention group
Intervention type: BEHAVIORAL
Intervention: Beta testing of MobileMen App Prototype
Description: Project staff present the clickable wireframe prototype and have men navigate and test features using a structured script. Staff track participant responses in notes, as well as through both recording via a side profile and the device screen. At the conclusion of the session, participants complete surveys measuring satisfaction, helpfulness, and usability.
Study NCT06461429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate: Low dose
Description: Lower dose caffeine: 20mg/kg load and 10mg/kg/day maintenance. Standard of care. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Study NCT05235854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection of corticosteroids (Diprostène®)
Description: Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.
Study NCT04222023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (IVIG)
Description: Experimental group: administration of a single dose of IVIG at:~* Day 10+/- 4 days~* Day 41 +/- 7 days~* Day 62 +/- 7 days The dose of IVIG is defined according the donor BKV genotype: genotype I: 0.4 g/Kg/day; genotype II and IV: 1g/kg/day.
Study NCT05655195 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GENUS device (Active Settings)
Description: Participants in the active, experimental group will use the GENUS devices configured to active (40Hz) setting for 60 minutes daily for 6 months.
Study NCT05655195 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS device (sham settings)
Description: Participants in the control group will use the GENUS devices configured to the sham settings for 60 minutes daily for 6 months.
Study NCT04476485 — intervention group
Intervention type: OTHER
Intervention: endocrine therapy
Description: If the expression of sj-subway in the surgical wax block is eligible, it is recommended but not mandatory that patients follow the guidelines to choose the appropriate extended endocrine therapy. 1. For postmenopausal patients: Extend treatment with aromatase inhibitors 10 years: letrozole or anastrozole or exemestane. 2. For premenopausal patients: An initial 5 years tamoxifen treatment followed by additional 5 years extended tamoxifen treatment. Postmenopausals are treated with aromatase inhibitors 5 years. 3. For patients have completed ovarian function suppression plus initial 5-year aromatase inhibitor treatment: Menopausals: Aromatase inhibitors; Non-menopausals: 5 years of tamoxifen treatment or ovarian function suppression plus 5 years of aromatase inhibitor treatment. 4. For patients have completed ovarian function suppression plus initial 5-year tamoxifen treatment: Menopausals: Aromatase inhibitors for additional 5 years; Non-menopausals: Tamoxifen for additional 5 years.
Study NCT05511480 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interference through learning of a competing motor skill.
Description: Interference through the learning of a competing motor skill.
Study NCT05511480 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No interference
Description: No interference through the continuation of learning same motor skill
Study NCT06409377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex 200 MCG in 2 ML Injection
Description: Patients received dexmedetomidine (1.5 μg/kg) as single injection over 10 minutes.
Study NCT06409377 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: C group:
Description: Patients received propofol (2 mg/kg), fentanyl (1 μg/kg), and atracurium (0.5 mg/kg).
Study NCT05049291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telehealth advance care planning
Description: An education information sheet containing prognosis and outcomes of acute care and intensive treatments
Study NCT06461429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate: Medium dose
Description: Medium dose caffeine: 30mg/kg load and 15 mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Study NCT06461429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate: High dose
Description: Higher dose caffeine: 40mg/kg load and 20mg/kg/day maintenance. Caffeine will be administered until at least 34+0 weeks' post-menstrual age, with the aim to cease caffeine by 36+0 weeks' post-menstrual age. Caffeine use beyond 36+0 weeks' post-menstrual age will be open-label.
Study NCT05445934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: FB2001 for injection will be reconstituted with 100 mL of normal saline prior to intravenous infusion. FB2001 will be administered by IV infusion over approximately 60 minutes.
Study NCT05445934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FB2001 placebo
Description: Placebo will be reconstituted with 100 mL of normal saline prior to intravenous infusion. Placebo will be administered by IV infusion over approximately 60 minutes.
Study NCT05366673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Perform a 10-minute back massage every day for a week
Study NCT04323566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 500 mg, dissolved in 250 ml NaCl in an infusion bag, covered with non-see-through plastic~* administered iv over a course of max 180 minutes~* at 0 and 4 months (treatment-first arme) OR at 8 and 12 months (placebo-first arm)
Study NCT05292196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC3721 suspension for inhalation
Description: TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
Study NCT05144334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTX-1188
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with BTX-1188 administered orally per dosing schedule.
Study NCT05292196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC3721 suspension placebo for inhalation
Description: TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
Study NCT06029530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Ophthalmic
Description: eye drops to be administered once daily
Study NCT05823558 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lomber Muscle Thickness Measurement
Description: Muscle thickness measurements will be made on the imaging of those who have lumbar MR imaging.
Study NCT06431542 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physician-applied Triamcinolone Acetonide Econazole Cream
Description: The doctor applies the Triamcinolone Acetonide Econazole Cream onto a thin cotton swab and gently inserts it deep into the ear canal, evenly spreading the cream around the sides of the ear canal and on the surface of the eardrum.
Study NCT05813834 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular Nerves Block
Description: US guided genicular nerves block
Study NCT06431542 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient-applied Triamcinolone Acetonide Econazole Cream
Description: The patient applies Triamcinolone Acetonide Econazole Cream in the external auditory canal at home using a cotton swab.
Study NCT05347459 — intervention group
Intervention type: DRUG
Intervention: Dapagliflozin
Description: usual and customary doses for type 2 diabetes management
Study NCT05347459 — intervention group
Intervention type: DRUG
Intervention: Empagliflozin
Description: usual and customary doses for type 2 diabetes management
Study NCT05347459 — intervention group
Intervention type: DRUG
Intervention: Canagliflozin
Description: usual and customary doses for type 2 diabetes management
Study NCT05347459 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin
Description: usual and customary doses for type 2 diabetes management
Study NCT05347459 — intervention group
Intervention type: DRUG
Intervention: Saxagliptin
Description: usual and customary doses for type 2 diabetes management
Study NCT05347459 — intervention group
Intervention type: DRUG
Intervention: Linagliptin
Description: usual and customary doses for type 2 diabetes management
Study NCT05347459 — intervention group
Intervention type: DRUG
Intervention: Vildagliptin
Description: usual and customary doses for type 2 diabetes management
Study NCT05490563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS-005
Description: SLS-005
Study NCT05490563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sodium chloride injection, 0.9%, USP)
Study NCT06345053 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: The intervention period will be from (May 2021- October 2024). All patients will participate in standard treatment at MBS. Dialectical Behaviour Therapy -Substance Use Disorder skills training (DBT-SUD skills) will be offered to all patients at MBS in the project period that experience difficulties in emotion regulation and manage to commit to participating in the DBT- skills training evaluated by their DBT therapist. Narrative Exposure Therapy (NET) will be offered to all patients with relevant traumatic experience and symptoms of PTSD depending on clinical evaluation.
Study NCT04130906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Theta Burst Stimulation
Description: iTBS will be delivered to the left dorsolateral prefrontal cortex (DLPFC) at 80% of resting motor threshold using standard stimulation parameters; triplet-bursts will be delivered at high frequency (50 Hz) with an inter-burst interval of 200 ms. Each TBS train will last 2 seconds and consists of 10 triplet-bursts (30 pulses). Each iTBS session will involve 10 TBS trains repeated every 10 seconds for 190 seconds, with a total number of 600 pulses delivered during each session.
Study NCT06260150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression Devices
Description: During use, the pressure is gradually reduced from large to small, and pressure is applied in steps, starting from the calf and moving up to the thigh. Every 30 minutes, the patient's skin color of the lower extremities is observed for any abnormalities, and the blood supply status of the distal ends of both lower limbs (palpation of the dorsalis pedis artery pulse) is noted. If any special conditions occur, the procedure must be immediately stopped.
Study NCT04130906 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intermittent Theta Burst Stimulation
Description: Sham stimulation will be delivered left dorsolateral prefrontal cortex (DLPFC) using the same parameters as real iTBS however, a sham coil will be used. The sham coil makes the same noise and creates a similar sensation on the scalp as the real coil but does not produce a magnetic field.
Study NCT05976815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Exercise
Description: Apart from the neoadjuvant chemotherapy treatment (standard of care), participants allocated to the experimental group will additionally participate in a supervised physical exercise program that comprises 3 weekly sessions during the months that the patient is undergoing chemotherapy treatment. Each 75-minute session will comprise a 10-minute warm up, 30 minutes of strength training involving exercise for the major muscle groups, 30 minutes of aerobic training at 40-89% of heart rate reserve and a 5-minute cool down.
Study NCT05319405 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sana Device
Description: Externally worn mask that physically contacts the skin of the face. The Sana Device delivers Audio Visual Stimulation (AVS) in the form of coordinated pulses of light (through closed eyelids) and sound at various frequencies.
Study NCT06192355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis using a Esophagogastroduodenoscopy
Description: performing an Esophagogastroduodenoscopy for diagnosis and therapy of possible bleeding sites
Study NCT05154162 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT
Description: PSMA PET/CT (limited to the pelvis)
Study NCT06192355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic hemostasis using a Esophagogastroduodenoscopy
Description: performing an Esophagogastroduodenoscopy for diagnosis and therapy of possible bleeding sites
Study NCT05154162 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transperineal template prostate biopsy
Description: Transperineal template prostate biopsies will be performed as per treating urologist's usual practice. No specific template for biopsy is prescribed for the purposes of the study. However, template sampling of the prostate is required, with a minimum of 12 cores, dependent on prostate volume. MRI will be available for any additional targeted biopsies required. Transperineal template biopsies must be labelled appropriately and sent for histopathological analysis.
Study NCT05154162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal targeted prostate biopsy
Description: If the PSMA PET/CT is normal, transperineal prostate biopsy would be omitted If the PSMA PET/CT is abnormal, transperineal prostate biopsies would be performed targeting the MRI (done prior to study) and PSMA PET/CT images
Study NCT05266040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 MG
Description: Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Valtrex (valacyclovir 500mg x three times daily for 7 days). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
Study NCT05266040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consistent with the pilot study VEII will use a random number generator to randomly assign a Manila packet containing amoxicillin 500mg + Placebo (empty capsule). Opaque medication packaging and using standardized verbal and written instructions helps ensure blindness of the VEII calibrated clinician, and patients of the therapeutic group they were assigned to.
Study NCT04678869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: prophylactic ciprofloxacin (10mg/kg BD, enteral/IV)
Study NCT04678869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Standard of care antibiotic as per local policy
Study NCT05631925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol bolus
Description: Propofol will be added in bolus doses of 0.5mg/kg.
Study NCT04613570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Upper gastrointestinal endoscopy
Description: In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;~* Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;~* EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:~* If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;~* If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;~* Antrum, incisura and corpus fragments should be sent in 3 separate vials;
Study NCT04613570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy
Description: In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made;~* Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial;~* EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification:~* If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol;~* If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area;~* Antrum, incisura and corpus fragments should be sent in 3 separate vials;
Study NCT05631925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol infusion
Description: Propofol will be administered as 10mg/kg/hour infusion.
Study NCT06163235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obemar platform
Description: Online platform for education and follow-up
Study NCT06193083 — intervention group
Intervention type: OTHER
Intervention: Semi-directed individual interviews
Description: Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)